natgillin/translations-raw huggingface dataset:
PC: {number} [product code] SN: {number} [serial number]
PC: {številka} [koda zdravila] SN: {številka} [serijska številka]
PC: {number} SN: {number} NN: {number}
PC: {številka} [koda zdravila] SN: {številka} [serijska številka]
pCav Range (ng/mL)
Razpon pCav (ng/ml)
pCR (absence ofinvasive neoplastic cells in breast
pCR (odsotnost invazivnih neoplastičnih celic v dojkah)
pCR rate in the breast and lymph node (ypT0/is N0) n (%) [95% CI]
p-vrednost (Simesova korekcija za test CMH)4
PCR-corrected cure rate (m-ITT)
Stopnja ozdravljenja, popravljena za PCR (m-ITT)
PCSK9 binds to the low-density lipoprotein receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver.
PCSK9 se veže na receptorje za lipoproteine majhne gostote (LDLR – low-density lipoprotein receptors) na površini jetrnih celic in pospeši razgradnjo LDLR v jetrih.
PCSK9 is a protein secreted by liver cells.
PCSK9 je beljakovina, ki jo izločajo jetrne celice.
PCSK9 lowers the number of these receptors in the liver – this causes your “bad” cholesterol to be higher than it should.
PCSK9 zmanjša število teh receptorjev v jetrih in tako povzroči, da je "slabega" holesterola več, kot bi ga smelo biti.
PCTFE / PVC / blisters with aluminium foil backing containing one clear blister of 11 x 0.5 mg and 14 x 1 mg film-coated tablets and a second clear blister of 28 x 1 mg film-coated tablets in secondary heat sealed card packaging.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v sekundarnem, toplotno zavarjenem pakiranju, ki vsebuje en prozoren pretisni omot z 11 filmsko obloženimi tabletami po 0,5 mg ter 14 filmsko obloženimi tabletami po 1 mg in drug prozoren pretisni omot z 28 filmsko obloženimi tabletami po 1 mg.
PCTFE / PVC / blisters with aluminium foil backing containing one clear blister of 11 x 0.5 mg film-coated tablets and a second clear blister containing 14 x 1 mg film-coated tablets in a carton.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v pakiranju, ki vsebuje en prozoren pretisni omot z 11 filmsko obloženimi tabletami po 0,5 mg in drug prozoren pretisni omot s 14 filmsko obloženimi tabletami po 1 mg v škatli.
PCTFE / PVC / blisters with aluminium foil backing containing one clear blister of 11 x 0.5 mg film-coated tablets and a second clear blister of 14 x 1 mg film-coated tablets in secondary heat sealed card packaging.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v sekundarnem, toplotno zavarjenem pakiranju, ki vsebuje en prozoren pretisni omot z 11 filmsko obloženimi tabletami po 0,5 mg in drug prozoren pretisni omot s 14 filmsko obloženimi tabletami po 1 mg.
PCTFE / PVC blisters with aluminium foil backing in a pack containing 28 x 0.5 mg film-coated tablets in secondary heat sealed card packaging.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v sekundarnem, toplotno zavarjenem pakiranju z 28 filmsko obloženimi tabletami po 0,5 mg.
PCTFE / PVC blisters with aluminium foil backing in a pack containing 56 x 0.5 mg film-coated tablets in secondary heat sealed card packaging.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v sekundarnem, toplotno zavarjenem pakiranju s 56 filmsko obloženimi tabletami po 0,5 mg.
PCTFE/ PVC / blisters with aluminium foil backing in a pack containing 112 x 1 mg film-coated tablets in a carton.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v pakiranju s 112 filmsko obloženimi tabletami po 1 mg v škatli.
PCTFE/ PVC / blisters with aluminium foil backing in a pack containing 140 x 1 mg film-coated tablets in a carton.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v pakiranju s 140 filmsko obloženimi tabletami po 1 mg v škatli.
PCTFE/ PVC / blisters with aluminium foil backing in a pack containing 28 x 1 mg film-coated tablets in a carton.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v pakiranju z 28 filmsko obloženimi tabletami po 1 mg v škatli.
PCTFE/ PVC / blisters with aluminium foil backing in a pack containing 56 x 1 mg film-coated tablets in a carton.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v pakiranju s 56 filmsko obloženimi tabletami po 1 mg v škatli.
PCTFE/ PVC blisters with aluminium foil backing in a pack containing 28 x 1 mg film-coated tablets in secondary heat sealed card packaging.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v sekundarnem, toplotno zavarjenem pakiranju z 28 filmsko obloženimi tabletami po 1 mg.
PCTFE/ PVC blisters with aluminium foil backing in a pack containing 56 x 1 mg film-coated tablets in secondary heat sealed card packaging.
Pretisni omoti iz PCTFE/PVC z aluminijasto prekrivno folijo v sekundarnem, toplotno zavarjenem pakiranju s 56 filmsko obloženimi tabletami po 1 mg.
PCTFE/PVC/Al-blister containing 14 film-coated tablets.
Pretisni omot iz PCTFE/PVC/Al, ki vsebuje 14 filmsko obloženih tablet.
PCTFE/PVC/Alu 18 months
PCTFE/PVC/Alu 18 mesecev
PCV2 associated infections may include symptoms such as weight loss or failure to grow, enlarged lymph nodes, difficulty breathing, diarrhoea, pale skin and jaundice (yellowing of the skin).
Okužbe, ki so povezane s PCV2, se kažejo s simptomi, kot so zmanjšanje telesne mase ali zastoj rasti, povečane bezgavke, oteženo dihanje, driska, bleda koža in zlatenica (rumeno obarvanje kože).
PCV2 ORF2 subunit antigen
PCV2 ORF2 podenota antigen
PCV2 ORF2 subunit antigen
PCV2, antigenska podenota ORF2
PCV2 ORF2 subunit antigen 1436 AU
PCV2 ORF2 podenota antigen 1436 AU
PCV2 ORF2 subunit antigen:  4.5 log2 ELISA units.
PCV2, antigenska podenota ORF2:  4,5 log2 enot ELISA
PCV2 ORF2 subunit antigen:  4.5 log2 ELISA units.
PCV2, antigenska podenota ORF2:  4.5 log2 enot ELISA
PD = progressive disease; PR = partial response; R = lenalidomide; SD = stable disease; VGPR = very good partial response. ª The median is based on the Kaplan-Meier estimate
PD = napredovanje bolezni; PR = delen odziv; R = lenalidomid; SD = stabilna bolezen; VGPR = zelo dober delen odziv. ª Mediana temelji na Kaplan-Meierjevi oceni.
PD = progressive disease; PR = partial response; R = lenalidomide; SD = stable disease; VGPR = very good partial response. ª The median is based on the Kaplan-Meier estimate
PD = napredovanje bolezni; PR = delni odziv; R = lenalidomid; SD = stabilna bolezen; VGPR = zelo dober delni odziv. ª Mediana temelji na Kaplan-Meierjevi oceni.
PD-L1 expression < 1%
Ekspresija PD-L1 < 1
PD-L1 expression was tested retrospectively by immunohistochemistry research assay with the 22C3 anti-PD-L1 antibody.
Testiranje ekspresije PD-L1 je bilo opravljeno retrospektivno z imunohistokemičnim preizkusom s protitelesom 22C3 proti PD-L1.
PD-L1 expression ≥ 1%
Ekspresija PD-L1 ≥ 1
PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to the foetus and to result in an increase in foetal loss.
Pokazalo se je, da zaviranje signalizacije PD-L1 v modelih brejosti pri miših okvari toleranco za plod in povzroči večjo izgubo plodov.
PD-L1 testing for patients with NSCLC
Testiranje PD-L1 pri bolnikih z NSCLC
PD-L2, RNA signature, etc.) predictive of pembrolizumab efficacy should be investigated together with more information regarding the pattern of expression of PD-L1 obtained in the ongoing melanoma studies (P001, P002 and P006) and NSCLC studies (P001, P010, P024 and P042):
PD-L2, RNA genetski podpis itd.), ki napovedujejo učinkovitost pembrolizumaba, skupaj z informacijami v zvezi z vzorcem izražanja PD-L1, ki je bil pridobljen v potekajočih študijah melanoma (P001, P002 in P006) in študijah NSCLC (P001, P010, P024 in P042):
PDE 5 inhibitors
Zaviralci PDE5
PDE-5 inhibitors for the treatment of erectile dysfunction (ED)
Zaviralec PDE-5 za zdravljenje erektilne disfunkcije (ED)
PDE-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH)
Zaviralec PDE-5 za zdravljenje pljučne arterijske hipertenzije (PAH)
PDE-5 inhibitors may be expected.
zvečanje koncentracije zaviralcev
PDE-5 inhibitors: sildenafil for the treatment of pulmonary arterial hypertension sedatives/hypnotics: orally administered midazolam, triazolam
nevroleptiki: pimozid zaviralci PDE-5: sildenafil za zdravljenje pljučne arterijske hipertenzije sedativi/hipnotiki: peroralno uporabljeni midazolam, triazolam
PDE-5 inhibitors: sildenafil for treatment of pulmonary arterial hypertension sedatives/hypnotics: orally administered midazolam, triazolam
nevroleptiki: pimozid zaviralci PDE-5: sildenafil za zdravljenje pljučne arterijske hipertenzije sedativi/hipnotiki: peroralno uporabljeni midazolam, triazolam
PDE4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells.
PDE4 je PDE, specifična za ciklični adenozinmonofosfat (cAMP), in prevladujoča PDE v vnetnih celicah.
PDE5 INHIBITOR
ZAVIRALEC PDE5
PDE5 inhibitor Avanafil Increased plasma concentrations of avanafil (see section 4.4. and 4.5).
Zaviralec PDE5 Avanafil Zvišana plazemska koncentracija avanafila (glejte poglavji 4.4 in 4.5).
PDE5 inhibitors
Zaviralci fosfodiesteraze tipa 5 (PDE5)
PDE5 inhibitors Avanafil Increased plasma concentrations of avanafil (see section 4.4. and 4.5).
Zaviralec PDE5 Avanafil Zvišana plazemska koncentracija avanafila (glejte poglavji 4.4 in 4.5).
PDE5 inhibitors including sildenafil
Zaviralci fosfodiesteraze tipa 5 (PDE5), vključno s sildenafilom
PDE5 inhibitors, such as ADCIRCA, have been shown to increase the hypotensive effects of this medicine.
Zaviralci PDE5, kot je ADCIRCA, dokazano povečujejo hipotenzivne učinke tega zdravila.
PDE5 inhibitors, such as Levitra have been shown to increase the hypotensive effects of this medicine.
Zaviralci PDE5, kot je zdravilo Levitra, dokazano povečujejo hipotenzivne učinke tega zdravila.
PDE5 inhibitors, such as Vivanza have been shown to increase the hypotensive effects of this medicine.
Zaviralci PDE5, kot je zdravilo Levitra, dokazano povečujejo hipotenzivne učinke tega zdravila.
PDS: improvement of at least 10%
PDS: izboljšanje za najmanj 10
PDS: improvement of at least 10%
PDS: izboljšanje za vsaj 10
PE with or without DVT
PE z GVT ali brez nje
PE/PI Event-Free Status, n (%)
stanje brez dogodka PE/PI, n (%)
Peach film-coated tablet of biconvex, oblong shape with the marking ‘500’ on the one side and ‘Xeloda’ on the other side.
Breskove barve, bikonveksne in podolgovate oblike z oznako “500” na eni strani in “Xeloda” na drugi strani.
Peach, round (approximately 8.7 mm in diameter), biconvex, film-coated tablets with both “A/P” and “25/30” printed in grey ink on one side.
Okrogle (premer približno 8,7 mm), bikonveksne, filmsko obložene tablete breskove barve z odtisnjenima sivima oznakama “A/P” in “25/30” na eni strani.
Peak axitinib concentrations in plasma are generally reached within 4 hours following oral administration of axitinib with median Tmax ranging from 2.5 to 4.1 hours.
Največje plazemske koncentracije aksitiniba se običajno dosežejo v 4 urah po peroralnem dajanju aksitiniba z mediano Tmax od 2,5 do 4,1 ure.
Peak blood concentrations achieved with these doses were above 150 nanogram/mL which is more than 6-fold higher than mean peak concentrations observed with Modigraf in clinical transplantation.
Najvišje koncentracije v krvi, dosežene s temi odmerki, so bile višje od 150 nanogram/ml, kar je več kot 6-krat višja vrednost od povprečne najvišje koncentracije, ki je bila opažena pri uporabi zdravila Modigraf pri presaditvah v klinični praksi
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/2) of 90 hours in plasma.
Koncentracijskemu vrhu je sledilo počasno pojemanje sistemskih učinkov z navideznim polovičnim časom izločitve (T ) okoli 90 ur v plazmi.
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/2) of approximately 91 hours in plasma.
Koncentracijskemu vrhu je sledilo počasno pojemanje sistemskih učinkov z navideznim polovičnim časom izločitve (T ) okoli 91 ur v plazmi.
Peak efavirenz plasma concentrations of 1.6 - 9.1 µM were attained by 5 hours following single oral doses of 100 mg to 1,600 mg administered to uninfected volunteers.
Maksimalne plazemske koncentracije efavirenza, 1,6 - 9,1 M, so bile pri neokuženih prostovoljcih dosežene 5 ur po dajanju enkratnih peroralnih odmerkov 100 mg do 1.600 mg.
Peak efavirenz plasma concentrations of 1.6 - 9.1 M were attained by 5 hours following single oral doses of 100 mg to 1,600 mg administered to uninfected volunteers.
Maksimalne plazemske koncentracije efavirenza, 1,6 - 9,1 M, so bile pri neokuženih prostovoljcih dosežene 5 ur po dajanju enkratnih peroralnih odmerkov 100 mg do 1.600 mg.
Peak efavirenz plasma concentrations of 1.6-9.1 microM were attained by 5 hours following single oral doses of 100 mg to 1,600 mg administered to uninfected volunteers.
Maksimalne plazemske koncentracije efavirenza, 1,6 - 9,1 µM, so bile pri neokuženih prostovoljcih dosežene 5 ur po dajanju enkratnih peroralnih odmerkov 100 mg do 1.600 mg.
Peak incidence of vaccine virus recovery occurred 1-2 days post-vaccination in clinical studies with Pandemic influenza vaccine H5N1 MedImmune.
Največjo pojavnost virusa iz cepiva so v kliničnih študijah s Cepivom proti pandemski gripi H5N1 MedImmune ugotovili 1 do 2 dneva po cepljenju.
Peak incidence of vaccine virus recovery occurred 2-3 days post-vaccination in Fluenz clinical studies.
V kliničnih študijah cepiva Fluenz je bila največja incidenca rekuperacije virusa iz cepiva 2 – 3 dni po cepljenju.
Peak Inspiratory Flow Rate through the Spiromax Device
Največja inspiratorna hitrost pretoka skozi pripomoček Spiromax
Peak Inspiratory Flow Rate through theSpiromax Device
Najvišja stopnja vdišnega toka z inhalatorjem Spiromax
Peak levels of aztreonam are achieved at about one hour after i.m. administration.
Najvišje ravni aztreonama so dosežene približno eno uro po i.m. uporabi.
Peak plasma concentrations (Cmax) of eslicarbazepine are attained at 2-3 hours post-dose and steady state plasma concentrations are attained after 4 to 5 days of once daily dosing, consistent with an effective half-life in the order of 20-24 h.
Najvišje koncentracije eslikarbazepina v plazmi (Cmax) so dosežene 2–3 ure po odmerku, koncentracije v stanju dinamičnega ravnovesja pa po 4 do 5 dneh odmerjanja enkrat na dan, kar je skladno z efektivnim razpolovnim časom 20–24 h.
Peak plasma concentrations (Cmax) of eslicarbazepine are attained at 2-3 hours post-dose and steady state plasma concentrations are attained after 4 to 5 days of once daily dosing, consistent with an effective half-life in the order of 20-24 hours.
Najvišje koncentracije eslikarbazepina v plazmi (Cmax) so dosežene 2–3 ure po odmerku, koncentracije v stanju dinamičnega ravnovesja pa po 4 do 5 dneh odmerjanja enkrat na dan, kar je skladno z efektivnim razpolovnim časom 20–24 h.
Peak plasma concentrations are reached at 6 hours following administration in a postoperative period due to contributing factors such as anaesthesia, gastrointestinal paresis, and surgical effects independent of the oral medicinal product formulation.
Koncentracije v plazmi so največje 6 ur po aplikaciji v pooperativnem obdobju, kar je posledica pridruženih dejavnikov, kot so anestezija, pareza prebavil in kirurški učinki in ni povezano s peroralno obliko zdravila.
Peak plasma levels (Cmax) of ceritinib are achieved approximately 4 to 6 hours after oral administration in patients.
Pri bolnikih doseže ceritinib najvišjo koncentracijo v plazmi (Cmax) približno 4 do 6 ur po peroralnem odmerjanju.
Peak plasma tedizolid concentrations are achieved within approximately 3 hours after dosing after oral administration of Sivextro under fasted conditions.
Najvišje koncentracije tedizolida v plazmi so dosežene v približno 3 urah po peroralnem odmerjanju zdravila Sivextro na tešče.
Peak serum concentration following intravenous infusion of 20 mg over 30 minutes is 7.15.1 mg/l.
Največja serumska koncentracija po 30-minutni intravenski infuziji 20 mg je 7,1 ± 5,1 mg/l.
Peak usage (33%) occurred during the first 12 months and remained similar from year to year.
12 mesecih, v naslednjih letih pa je odstotek uporabe ostal podoben.
PEARL I was conducted in the US and Europe, M12- 536 in Japan.
Študija PEARL I je potekala v ZDA in Evropi, M12-536 pa na Japonskem.
PEARL II, III, and IV
PEARL II, III in IV
Pearl Index
Pearlov
Pearl Index
Pearlu
Pearl Indices (see table):
Pearlov indeks (glejte preglednico):
PEARL- I– genotype 4, treatment-naïve or pegIFN + RBV experienced without cirrhosis
PEARL- I– genotip 4, še nezdravljeni ali že zdravljeni s kombinacijo pegIFN + RBV, brez ciroze
PEARL-II was a randomised, global multicentre, open-label trial conducted in 179 adults with chronic genotype 1b hepatitis C virus infection without cirrhosis who did not achieve SVR with prior treatment with pegIFN/RBV.
Preskušanje PEARL-II je bilo globalno multicentrično, randomizirano, odprto preskušanje pri 179 odraslih, ki so imeli kronično okužbo z virusom hepatitisa C genotipa 1b brez ciroze in s predhodnim zdravljenjem s pegIFN/RBV niso dosegli SVR.
PEARL-II – genotype 1b, pegIFN+RBV-experienced, without cirrhosis
PEARL-II – genotip 1b, že zdravljeni s pegIFN + RBV, brez ciroze
PEARL-II – genotype 1b, peginterferon+ribavirin-experienced
PEARL-II – genotip 1b, že zdravljeni s peginterferonom+ribavirinom
PEARL-III was a randomised, global multicentre, double-blind, controlled trial conducted in 419 treatment-naïve adults with genotype 1b chronic hepatitis C virus infection without cirrhosis.
Preskušanje PEARL-III je bilo globalno multicentrično, randomizirano, dvojno slepo, kontrolirano preskušanje pri 419 še nezdravljenih odraslih, ki so imeli kronično okužbo z virusom hepatitisa C genotipa 1b brez ciroze.
PEARL-III – genotype 1b, treatment-naïve
PEARL-III – genotip 1b, še nezdravljeni
PEARL-III – genotype 1b, treatment-naïve, without cirrhosis
PEARL-III – genotip 1b, še nezdravljeni, brez ciroze
PEARL-IV was a randomised, global multicentre, double-blind, controlled trial conducted in 305 treatment-naïve adults with genotype 1a chronic hepatitis C virus infection without cirrhosis.
Preskušanje PEARL-IV je bilo globalno, multicentrično, randomizirano, dvojno slepo, kontrolirano preskušanje pri 305 še nezdravljenih odraslih, ki so imeli kronično okužbo z virusom hepatitisa C genotipa 1a brez ciroze.
PEARL-IV – genotype 1a, treatment-naïve, without cirrhosis
PEARL-IV – genotip 1a, še nezdravljeni, brez ciroze
PEARL-IV– genotype 1a, treatment-naïve
PEARL-IV– genotip 1a, še nezdravljeni
PecFent
PecFent   placebo
PecFent 100 micrograms/spray nasal spray Fentanyl
PecFent 100 mikrogramov/vpih pršilo za nos fentanil
PecFent 100 micrograms/spray nasal spray solution Fentanyl
PecFent 100 mikrogramov/vpih pršilo za nos, raztopina fentanil
PecFent 100 micrograms/spray nasal spray, solution
PecFent 100 mikrogramov/vpih pršilo za nos, raztopina
PecFent 100 micrograms/spray nasal spray, solution PecFent 400 micrograms/spray nasal spray, solution Fentanyl
PecFent 100 mikrogramov/vpih pršilo za nos, raztopina PecFent 400 mikrogramov/vpih pršilo za nos, raztopinafentanil
PecFent 2 spray bottles in their child resistant containers are supplied in a carton containing 1 bottle.
Steklenice zdravila PecFent z 2 vpihoma v vsebnikih z zaporko, varno za otroke, se dobavljajo v škatlah z 1 steklenico.
PecFent 400 micrograms/spray nasal spray Fentanyl
PecFent 400 mikrogramov/vpih pršilo za nos fentanil
PecFent 400 micrograms/spray nasal spray solution Fentanyl
PecFent 400 mikrogramov/vpih pršilo za nos, raztopina fentanil
PecFent 400 micrograms/spray nasal spray, solution
PecFent 400 mikrogramov/vpih pršilo za nos, raztopina
PecFent comes in two different strengths: a 100 microgram per spray bottle and a 400 microgram per spray bottle.
Zdravilo PecFent je na voljo v dveh različnih jakostih: steklenica s 100 mikrogrami/vpih in steklenica s 400 mikrogrami/vpih.
PecFent contains propylparahydroxybenzoate (E216).
Zdravilo PecFent vsebuje propilparahidroksibenzoat (E216).
PecFent could be life-threatening if taken by a child by accident.
Če otrok po nesreči vzame zdravilo PecFent, je to lahko smrtno nevarno.
PecFent excipients
Pomožne snovi v zdravilu PecFent
PecFent is a nasal spray that contains the active substance fentanyl (100 and 400 micrograms per spray).
Zdravilo PecFent je pršilo za nos, ki vsebuje zdravilno učinkovino fentanil (100 in 400 mikrogramov na vpih pršila).
PecFent is a nasal spray, solution
Zdravilo PecFent je pršilo za nos, raztopina.
PecFent is a ‘hybrid generic medicine’.
Zdravilo PecFent je „hibridno generično zdravilo“.
PecFent is for nasal use only.
Zdravilo PecFent je namenjeno samo za nazalno uporabo.
PecFent is indicated for the management of breakthrough pain (BTP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain.
Zdravilo PecFent je indicirano za obvladovanje prebijajoče bolečine (BTP – breakthrough pain) pri odraslih, ki že prejemajo vzdrževalno opioidno terapijo za kronično bolečino zaradi raka.
PecFent is not recommended for use in patients who have received monoamine oxidase (MAO) inhibitors within the previous 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics.
Zdravilo PecFent se ne priporoča pri bolnikih, ki so v zadnjih 14 dneh dobili zaviralce monoamin- oksidaze (MAO), saj poročajo o resnih in nepredvidljivih povečanjih učinkov zaviralcev MAO z opioidnimi analgetiki.
PecFent is only to be used by spraying into your nostril.
Zdravilo PecFent smete uporabljati samo tako, da si ga pršite v nosnico.
PecFent is used in adults with cancer for a type of pain called ‘breakthrough’ pain.
Zdravilo PecFent se uporablja pri odraslih z rakom za vrsto bolečine, ki se imenuje ‘prebijajoča’ bolečina.
PecFent is used in patients who are already using opioids (a group of painkillers that includes morphine and fentanyl) to control long-term cancer pain.
Zdravilo PecFent se uporablja pri bolnikih, ki že jemljejo opioide (zdravila iz skupine protibolečinskih zdravil, kamor spadata morfin in fentanil) za nadzor dolgotrajne bolečine pri raku.
PecFent is used to treat ‘breakthrough’ pain in adult patients (aged 18 years or over) with cancer. ‘Breakthrough pain’ is when a patient experiences additional, sudden pain in spite of ongoing treatment with painkillers.
Zdravilo PecFent se uporablja za zdravljenje „prebijajoče“ bolečine pri odraslih bolnikih (starih 18 let ali več) z rakom.
PecFent must not be used in patients who are not already taking opioids to maintain pain control, who have severe respiratory depression (inhibition of breathing) or who have severe obstructive lung conditions (diseases that severely impede breathing).
Zdravila PecFent ne smejo uporabljati bolniki, ki še ne jemljejo opioidov za vzdrževanje nadzora nad bolečino, kakor tudi ne tisti, ki imajo resno respiratorno depresijo (oteženo dihanje) ali obolenje s hudo obstrukcijo pljuč (bolezen, pri kateri je dihanje močno ovirano).
PecFent nasal spray should be prescribed only by physicians experienced in the management of opioid therapy in cancer patients.
Pršilo za nos PecFent smejo predpisovati samo zdravniki, ki imajo izkušnje z vodenjem opioidnega zdravljenja pri bolnikih z rakom.
PecFent nasal spray should not be used to treat any other short-term pain or pain status.
Pršilo za nos PecFent se ne sme uporabljati za zdravljenje kake druge kratkoročne bolečine ali bolečinskega stanja.
PecFent that has passed the expiry date or is no longer required may still contain enough medicine to be harmful to other people, especially children.
Zdravilo PecFent, ki mu je potekel rok uporabnosti ali ga ne potrebujete več, lahko še vedno vsebuje dovolj zdravila, da je lahko škodljivo za druge ljudi, predvsem otroke.
PecFent was more effective than placebo in treating breakthrough cancer pain.
Zdravilo PecFent je bilo pri zdravljenju prebijajoče bolečine pri raku učinkovitejše od placeba.
pecies
živalska
pecies administration
ubkutana uporaba
pecific lung disease with difficulties breathing (called interstitial lung disease)
posebna bolezen pljuč z oteženim dihanjem (imenovana intersticijska pljučna bolezen),
pecific medicines for the treatment of bronchial asthma (β-sympathomimetics)
določena zdravila za zdravljenje bronhialne astme (β-simpatomimetiki);